Clinical trial
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia…
NCT00111891 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00111891 |
|---|---|
| Title | An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032) |
| Official title | A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dyslipidemia |
| Intervention type | Drug |
| Interventions | niacin (+) laropiprant, Comparator: placebo (unspecified) |
| Enrollment | 575 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | May 27, 2005 |
| Last update posted | Feb 17, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: